Tato stránka byla automaticky přeložena a přesnost překladu není zaručena. Podívejte se prosím na anglická verze pro zdrojový text.

Urinary DNA Methylation Testing (Bladder EpiCheck®) and Its Peri-operative Kinetics for the Prediction of Residual Disease at Second Transurethral Resection in T1 Non-muscle-invasive Bladder Cancer (EPIRE)

13. listopadu 2026 aktualizováno: Istituto Oncologico Veneto IRCCS

Urinary DNA Methylation Testing (Bladder EpiCheck®) and Its Peri-operative Kinetics for the Prediction of Residual Disease at Second Transurethral Resection in T1 Non-muscle-invasive Bladder Cancer The EPIRE Study

European Association of Urology (EAU) guidelines mandate a second transurethral resection of bladder tumour (re-TURBt) for patients with high-grade or pT1 non-muscle-invasive bladder cancer (NMIBC) to eradicate residual disease and avoid understaging. However, 30% to 50% or more of patients undergoing re-TURBt have no residual tumour found upon re-resection, incurring surgical and anaesthetic risks, potential morbidity, healthcare costs, and delays in adjuvant therapy without direct oncological benefit.

Current non-invasive triage tools, such as urine cytology and office cystoscopy, suffer from low sensitivity or diagnostic ambiguity due to ongoing post-operative inflammation and tissue healing in a recently resected bladder. While novel molecular biomarkers like Bladder EpiCheck® demonstrate high sensitivity and negative predictive value in the surveillance setting, single-timepoint measurements shortly after resection struggle to differentiate transient, healing-induced epigenetic changes from true persistent malignancy.

Evaluating the longitudinal trajectory of the EpiScore across two distinct post-operative timepoints (T1 and T2) provides a physiological basis for distinguishing decaying inflammatory/reparative signals from stable or rising signals indicative of residual disease. Demonstrating the diagnostic accuracy of Bladder EpiCheck® at T2, alongside the dynamic change in EpiScore (ΔEpiScore), will establish whether non-invasive urine biomarker testing can reliably select low-risk pT1 NMIBC patients in whom re-TURBt can be safely omitted.

Přehled studie

Postavení

Zatím nenabíráme

Podmínky

Intervence / Léčba

Typ studie

Intervenční

Zápis (Odhadovaný)

60

Fáze

  • Nelze použít

Kontakty a umístění

Tato část poskytuje kontaktní údaje pro ty, kteří studii provádějí, a informace o tom, kde se tato studie provádí.

Studijní kontakt

Studijní záloha kontaktů

Studijní místa

Kritéria účasti

Výzkumníci hledají lidi, kteří odpovídají určitému popisu, kterému se říká kritéria způsobilosti. Některé příklady těchto kritérií jsou celkový zdravotní stav osoby nebo předchozí léčba.

Kritéria způsobilosti

Věk způsobilý ke studiu

18 let až 99 let (Dospělý, Starší dospělý)

Přijímá zdravé dobrovolníky

Ne

Pohlaví způsobilá ke studiu

Všechno

Popis

Inclusion Criteria:

  • age ≥18 years;
  • histologically confirmed pT1 urothelial carcinoma of the bladder (any grade, WHO 2022 and 1973 classifications) on the definitive histology of the initial TURBt;
  • macroscopically complete initial resection as reported by the surgeon, with detrusor muscle present in the specimen, both formally documented in the operative and pathology records;
  • indication for second TURBt according to EAU guidelines, with the procedure scheduled at the study centre and expected within ten weeks of the initial TURBt;
  • clinically localised non-metastatic disease (cN0, cM0);
  • patients able to provide written informed consent.
  • Previous BCG treatment is allowed.

Exclusion Criteria:

  • muscle-invasive disease (≥pT2) on the definitive histology of the initial TURBt;
  • initial resection judged incomplete by the operating surgeon - whether because visible tumour was deliberately left behind or because the procedure had to be curtailed and a planned second look arranged - or absence of detrusor muscle in the specimen - these patients receive second TURBt per guidelines but are outside the study question, which concerns the completely resected patient;
  • pure non-urothelial histology (primary adenocarcinoma, pure squamous cell carcinoma, small cell neuroendocrine carcinoma, sarcoma). Variant histologies of urothelial carcinoma are not an exclusion criterion but are recorded as a covariate;
  • concomitant upper tract urothelial carcinoma, or a history of it within the preceding 24 months, given the documented positivity of Bladder EpiCheck® in that disease [19];
  • A single early post-operative chemotherapy instillation, where given, is not an exclusion criterion but is recorded as a covariate;
  • previous pelvic radiotherapy;
  • indwelling urinary catheter or intermittent self-catheterisation; urinary diversion or neobladder;
  • clinically non-localised disease (cN+, cM+);
  • pregnancy or breastfeeding;
  • TURBt performed in an emergency setting for uncontrolled bleeding or other life-threatening indication, in which resection quality cannot be assured;
  • second TURBt not performed at the study centre, with consequent unavailability of the reference standard;
  • patients unable to provide written informed consent, or any condition that in the investigator's judgement compromises the ability to comply with study procedures.

Studijní plán

Tato část poskytuje podrobnosti o studijním plánu, včetně toho, jak je studie navržena a co studie měří.

Jak je studie koncipována?

Detaily designu

  • Primární účel: Diagnostický
  • Přidělení: N/A
  • Intervenční model: Přiřazení jedné skupiny
  • Maskování: Žádné (otevřený štítek)

Zbraně a zásahy

Skupina účastníků / Arm
Intervence / Léčba
Experimentální: EPIRE

The investigational IVD medical device evaluated as the index test is the Bladder EpiCheck® system (manufactured by Nucleix Ltd.; exclusive Italian distributor: A. Menarini Diagnostics s.r.l.). The assay is CE-IVD marked under Directive 98/79/EC (Annex III, General IVD category) and cleared by the US FDA via the 510(k) pathway. The manufacturer operates under a certified UNI CEI EN ISO 13485:2016 quality management system. Bladder EpiCheck® profiles the DNA methylation patterns of 15 proprietary DNA biomarkers on genomic DNA isolated from the cellular pellet of a voided urine sample. The assay protocol involves DNA extraction, digestion with a methylation-sensitive restriction enzyme, and subsequent multiplex real-time polymerase chain reaction (multiplex real-time PCR).

Dedicated analysis software generates a quantitative integrative score termed the EpiScore, on a continuous scale from 0 to 100. In accordance with the manufacturer's Instructions for Use (IFU), the qualitative diagno

Co je měření studie?

Primární výstupní opatření

Měření výsledku
Popis opatření
Časové okno
Diagnostic accuracy of Bladder EpiCheck® test at timepoint T2 for residual disease at second TURBt in T1 NMIBC patients.
Časové okno: Through study completion, an average of 2 years

Diagnostic accuracy of EpiScore at T2 (categorized as > 60 positive vs ≤ 60 negative) evaluated against central histopathology review of the second TURBt, measured as Sensitivity, Specificity, Positive Predictive Value (PPV), Negative Predictive Value (NPV), Accuracy, and Likelihood Ratios.

Through study completion, an average of 2 years
Diagnostic accuracy of change EpiScore between the two subsequent timepoints T1 and T2.
Časové okno: Through study completion, an average of 2 years

Average daily rate of change in EpiScore, calculated as ∆EpiScore=(T2-T1)/(Days between T1 and T2) evaluated against second TURBt residual disease status using a univariate logistic regression model and Area Under the ROC Curve (AUC) with 95% CI.

Through study completion, an average of 2 years

Sekundární výstupní opatření

Měření výsledku
Popis opatření
Časové okno
Diagnostic accuracy of Bladder EpiCheck® test at timepoint T1
Časové okno: Through study completion, an average of 2 years

Sensitivity, Specificity, PPV, NPV, Accuracy, and Likelihood Ratios (95% CI) of EpiScore at T1 (> 60 vs ≤ 60) for residual disease at second TURBt

Through study completion, an average of 2 years
Diagnostic accuracy of urinary cytology at timepoints T1 and T2
Časové okno: Through study completion, an average of 2 years

Sensitivity, Specificity, PPV, NPV, Accuracy, and Likelihood Ratios (95% CI) of urinary cytology (Paris System classification) at T1 and T2 against second TURBt histopathology

Through study completion, an average of 2 years
Agreement at T1 and T2 between Bladder EpiCheck® and urinary cytology
Časové okno: Through study completion, an average of 2 years

Concordance between Bladder EpiCheck® and urinary cytology at T1 and T2, quantified by Cohen's kappa (κ) coefficient.

Through study completion, an average of 2 years
Agreement between T1 and T2 of Bladder EpiCheck®;
Časové okno: Through study completion, an average of 2 years

Agreement on paired aliquots of Bladder EpiCheck® between timepoints T1 and T2 with McNemar's test for paired data

Through study completion, an average of 2 years
Agreement between T1 and T2 of urinary cytology
Časové okno: Through study completion, an average of 2 years

Agreement on paired aliquots of urinary cytology between timepoints T1 and T2 with McNemar's test for paired data

Through study completion, an average of 2 years
Diagnostic accuracy at T1 and T2 of the combination of Bladder EpiCheck® and urinary cytology, defined in two versions: (1) as negative when both are negative, (2) as negative when at least one is negative
Časové okno: Through study completion, an average of 2 years

Sensitivity, Specificity, PPV, NPV, and Accuracy at T1 and T2 evaluated under two combination definitions: (1) negative when both tests are negative; (2) negative when at least one test is negative

Through study completion, an average of 2 years
Diagnostic accuracy in the previous settings for predicting high-grade disease, ≥ pT1, and/or concomitant Carcinoma in Situ (CIS) at second TURBt;
Časové okno: Through study completion, an average of 2 years

Diagnostic accuracy measures (Sensitivity, Specificity, PPV, NPV) of tests and combinations specifically for predicting high-grade disease, ≥ pT1, and/or concomitant Carcinoma in Situ (CIS) at second TURBt

Through study completion, an average of 2 years
Diagnostic accuracy of alternative definitions of change in EpiScore
Časové okno: Through study completion, an average of 2 years

Diagnostic accuracy and AUC for alternative definitions of Episcore change between T1 and T2: absolute difference (T2-T1) and relative percentage change (T2-T1)/T1;

Through study completion, an average of 2 years
Change in positivity rate of Bladder EpiCheck® and urinary cytology between T1 and T2 among patients whose second TURBt is negative.
Časové okno: Through study completion, an average of 2 years

9) Proportion of test positivity change between T1 and T2 in patients without residual disease (measuring the clearance rate of post-operative false positives).

Through study completion, an average of 2 years

Spolupracovníci a vyšetřovatelé

Zde najdete lidi a organizace zapojené do této studie.

Sponzor

Spolupracovníci

Termíny studijních záznamů

Tato data sledují průběh záznamů studie a předkládání souhrnných výsledků na ClinicalTrials.gov. Záznamy ze studií a hlášené výsledky jsou před zveřejněním na veřejné webové stránce přezkoumány Národní lékařskou knihovnou (NLM), aby se ujistily, že splňují specifické standardy kontroly kvality.

Hlavní termíny studia

Začátek studia (Odhadovaný)

31. ledna 2027

Primární dokončení (Odhadovaný)

31. ledna 2029

Dokončení studie (Odhadovaný)

31. ledna 2029

Termíny zápisu do studia

První předloženo

13. listopadu 2026

První předloženo, které splnilo kritéria kontroly kvality

13. listopadu 2026

První zveřejněno (Aktuální)

19. listopadu 2026

Aktualizace studijních záznamů

Poslední zveřejněná aktualizace (Aktuální)

19. listopadu 2026

Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality

13. listopadu 2026

Naposledy ověřeno

1. listopadu 2026

Více informací

Termíny související s touto studií

Další identifikační čísla studie

  • IOV-NMIBC-02-2026-EPIRE

Plán pro data jednotlivých účastníků (IPD)

Plánujete sdílet data jednotlivých účastníků (IPD)?

NEROZHODNÝ

Informace o lécích a zařízeních, studijní dokumenty

Studuje lékový produkt regulovaný americkým FDA

Ne

Studuje produkt zařízení regulovaný americkým úřadem FDA

Ne

Tyto informace byly beze změn načteny přímo z webu clinicaltrials.gov. Máte-li jakékoli požadavky na změnu, odstranění nebo aktualizaci podrobností studie, kontaktujte prosím register@clinicaltrials.gov. Jakmile bude změna implementována na clinicaltrials.gov, bude automaticky aktualizována i na našem webu .